Sciwind Biosciences Co., Ltd. has recently announced positive results from Phase 1 and Phase 3 studies of their innovative therapy, ecnoglutide, for patients with type 2 diabetes (T2DM). The Phase 1 study showed that oral ecnoglutide was safe, well-tolerated, and resulted in significant weight loss. Additionally, the Phase 3 study with weekly subcutaneous ecnoglutide demonstrated robust declines in HbA1c levels, with a substantial number of participants reaching normoglycemia.
Moreover, the company has identified novel amylin analogs that showed potent activity and when combined with ecnoglutide, resulted in a synergistic effect on weight reduction in preclinical models. This combination was more effective than other combinations, showing promise for improved outcomes for patients with metabolic diseases like obesity and T2DM.
Sciwind Biosciences will be presenting their findings at the American Diabetes Association’s 84th Annual Conference in Orlando, FL. The presentations will cover the safety, efficacy, and pharmacokinetics of oral ecnoglutide, as well as the results from the Phase 3 evaluation of injectable ecnoglutide in adults with T2DM. Additionally, they will share data on the discovery of a novel amylin receptor agonist for body weight control and the synergistic effects of ecnoglutide and amylin analogs in preclinical animal models.
Ecnoglutide is a novel GLP-1 analog optimized for improved biological activity and cost-effective manufacturing. It has shown benefits for patients with T2DM and obesity, with promising results in clinical studies. Sciwind Biosciences is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for metabolic diseases like T2DM.
For more information on Sciwind Biosciences and their product pipeline, including ecnoglutide and other drug candidates, visit their website at http://www.sciwindbio.com. Stay tuned for updates from the ADA conference to learn more about the exciting advancements in the field of metabolic disease treatment.
Source link